Technique for replacing the mitral valve with a pulmonary autograft: the Ross-Kabbani operation

Kabbani, Sami S.; Jamil, Hisham; Hammoud, A

doi:10.1016/s0003-4975(01)02731-x

Cited by 15 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These characteristics are attractive, even though the procedure is complex and time-consuming. Although there have been several modifications, 4,9 we prefer the top hat technique, 8 because we believe that the proximal pericardial collar fixation is important to prevent instability or deformity in this fully flexible tubing graft. Whether the pulmonic valve is restrained within a prosthetic tube graft seems less important.…”

Section: Discussionmentioning

confidence: 99%

“…2,3 In patients with irreparable mitral valvulopathy complicated with chronic atrial fibrillation, addition of some sort of ablative procedure has been recommended to make its benefits more complete. 4 Currently, a stentless bioprosthesis is accepted as the right ventricular outflow tract (RVOT) substitute of choice in the Ross procedure. 4,5 We report on 2 patients who had satisfactory results with the use of a Freestyle aortic root bioprosthesis (Medtronic, Inc, Minneapolis, Minn) for RVOT reconstruction in the Ross II procedure combined with the radiofrequency maze IV procedure that was developed in our center.…”

mentioning

confidence: 99%

“…4 Currently, a stentless bioprosthesis is accepted as the right ventricular outflow tract (RVOT) substitute of choice in the Ross procedure. 4,5 We report on 2 patients who had satisfactory results with the use of a Freestyle aortic root bioprosthesis (Medtronic, Inc, Minneapolis, Minn) for RVOT reconstruction in the Ross II procedure combined with the radiofrequency maze IV procedure that was developed in our center. 6,7 Clinical Summaries PATIENT 1.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Combination of the Ross II operation with stentless bioprosthesis and radiofrequency maze IV operation

Chang

Kao

et al. 2002

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Combination of the Ross II operation with stentless bioprosthesis and radiofrequency maze IV operation

Chang

Kao

et al. 2002

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

“…The operative technique evolved through a number of stages, and has been described in full in previous reports. 5,7 Briefly, when it is decided that the MV cannot be repaired, our current technique entails excising a flap of pericardium, taking down the pulmonary artery, and suturing a proper sized homograft or xenograft in its place. Our preference is to use a pulmonary homograft whenever possible.…”

Section: Methodsmentioning

confidence: 99%

Update on the mitral pulmonary autograft

Kabbani

Sabbagh

Kudsi

et al. 2011

Asian Cardiovasc Thorac Ann

Self Cite

View full text Add to dashboard Cite

Between July 1997 and August 2004, 92 patients with irreparable mitral valves underwent replacement with a pulmonary autograft. This report brings the follow-up data of these patients up to date. Eighty-eight patients had a successful Ross II operation; 4 were lost to follow-up. The mean follow-up period was 94 months. Transesophageal echocardiography revealed a successful outcome in all 88 patients immediately after the operation. Operative mortality was 4.6%, and late mortality definitely related to the operation was 12.5%. At a mean follow-up of 94 months, freedom from structural valve deterioration (significant mitral stenosis and/or regurgitation) was 93.4%, freedom from reoperation was 92.0%, and freedom from all causes of death was 82.9%. Two autografts were explanted because of endocarditis. Two patients developed significant pulmonary stenosis, one of whom underwent operative repair. These data compare favorably with those of mitral valve replacement using modern bioprostheses. This procedure remains an option for the relatively young patient when life-long anticoagulation is contraindicated or impractical. It is also an option to consider in infants with complex irreparable mitral valve disease.

show abstract

“…A durable tissue valve that was cost-effective and did not require long-term anticoagulation was the leading impetus for their interest in the Ross II procedure. 2,11,12 Kabbani et al, in Syria, have the largest published series which includes 92 patients, most with rheumatic heart disease. 3 They report an in-hospital mortality rate of 4.5%.…”

Section: Commentmentioning

confidence: 99%

Pulmonary Autograft Mitral Valve Replacement (Ross II): Long-Term Follow-Up of a US Center

Blitzer

Herrmann

Brown

2018

World J Pediatr Congenit Heart Surg

View full text Add to dashboard Cite

Background: Mitral valve replacement (MVR) with a pulmonary autograft (Ross II) may be a useful technique for pediatric and young adult patients who wish to avoid anticoagulation. Our aim was to evaluate the long-term outcomes of the Ross II procedure at our institution. Methods: Patients undergoing the Ross II procedure between June 2002 and April 2008 were included. Preoperative diagnoses included rheumatic disease (n ¼ 5), congenital mitral valve (MV) pathology (partial atrioventricular canal defect [n ¼ 2], complete atrioventricular canal defect [n ¼ 1], Shone's complex [n ¼ 1]), and myocarditis (n ¼ 1). Results: Ten patients (eight females and two males) between 7 months and 46 years were included. Mean age at surgery was 25.2 + 15.7 years. There were no in-hospital deaths. Mean follow-up was 11.7 + 5.2 years. There were three late deaths at 11 months, 5 years, and 11 years, respectively. Causes of death included right heart failure, sepsis, and sudden cardiac arrest. Three patients required subsequent mechanical MVR a median of two years after the Ross II procedure (range: 1-4 years). There was no mortality with reoperation. Echocardiographic follow-up demonstrated mean MV gradients ranging from 2.2 to 9.6 mm Hg. Two patients had greater than mild MV regurgitation postoperatively, and all others had minimal mitral regurgitation or less. Two patients developed moderate MV stenosis. Conclusions: The Ross II procedure is an option for select older children and young adults desiring a durable tissue MVR to avoid long-term anticoagulation.

show abstract

Technique for replacing the mitral valve with a pulmonary autograft: the Ross-Kabbani operation

Cited by 15 publications

References 4 publications

Combination of the Ross II operation with stentless bioprosthesis and radiofrequency maze IV operation

Combination of the Ross II operation with stentless bioprosthesis and radiofrequency maze IV operation

Update on the mitral pulmonary autograft

Pulmonary Autograft Mitral Valve Replacement (Ross II): Long-Term Follow-Up of a US Center

Contact Info

Product

Resources

About